Role of AI in Clinical Trials
Introduction
A branch of computer science called artificial intelligence (AI) seeks to understand how the human brain makes decisions and solves problems. The application of AI does not make it novel; it has been around for over a century. Though this is rarely discussed, AI has been utilized to assist with the increasing complexity of medication development over the past few decades. The role of AI in clinical trials is projected to grow from 2.4 in 2024 to 6.4 by 2032, at a CAGR of 23.20%. One well-known example is the use of AI models to assist in determining how chemical compounds' structures influence how they function in live organisms. They are crucial for discovering novel medications and assisting researchers in forecasting how a possible medication will function in the body.
They have made the process of discovering new medications considerably more effective by allowing scientists to concentrate on potential medications that have a higher likelihood of combating a particular ailment, even though their estimates are constrained by what the models can do. Our current challenges include combating far more complex diseases with greater accuracy, safety, and efficacy than was previously achievable. Fortunately, because to strong and affordable technology, we have access to a wealth of data on human biology as well as the ability to analyze vast amounts of information. The difficulty of treating these complex ailments has increased along with AI's capacity to do it.
Traditional approaches to sickness detection frequently overlook characteristics that could be found using computational techniques and algorithms because they rely on a single predetermined hypothesis. As we evaluate treatment choices, several targets may be taken into consideration simultaneously. Humans are not capable of multitasking. AI aids in closing that gap, but it still needs human guidance.
Role and application of AI in clinical trials
The people in charge of a clinical study's initial stages may determine its outcome. The trial's potential for effectiveness will increase if participants are successfully identified; however, patient selection and recruitment may require a significant amount of time and resources. Ineffective or sluggish recruitment attempts may be the cause of a study's failure. The possibility of financial loss should be viewed as an incentive to employ AI technology at the initial stages of clinical trials. AI is capable of sorting through vast amounts of data to find patient subgroups that might benefit from a clinical study. The recruitment effort might be concentrated by identifying hotspots for a disease or ailment through the analysis of social media content.
Technology has the potential to simplify previously complex admissions standards, making them more accessible to eligible candidates. Using AI to sift through reams of medical data can help identify potential clinical trial volunteers. Researchers at Mount Sinai Medical Center in New York, for example, used topological data analysis (TDA) to classify persons with type 2 diabetes into three groups based on their electronic health records (EHRs) and genetic data. The TDA's clinical feature and ailment comorbidity patterns provided insights on how particular patients will react to a treatment or a clinical trial. AI-based patient identification is cutting-edge in fields such as social media data analysis. AI can sort through patient support groups.
This strategy may aid in the rapid identification of cohorts, allowing businesses to more efficiently plan clinical trials. Once a target population has been identified, AI can help in recruitment. The usage of AI may streamline the hiring process and eliminate unnecessary inspections.
One of the challenges of conducting distributed clinical trials is dealing with the huge amounts of data that must be collected and processed. Patients must actively and consistently supply their own participation data because they are not present throughout the trial. This may cause issues with patient compliance and informational inaccuracies. Medical research organizations and contract research organizations (CROs) may employ AI to address these issues in a variety of ways. In this case, the intended goal is regular patient compliance, which can be achieved by developing algorithms that analyze patient data and make decisions.
The quality of data submitted by patients may be assessed by AI programs before acceptance, which can be extremely beneficial to patients. An AI system, for example, may assess a photograph to see if it satisfies the parameters for a clinical research. It may then advise the patient on how to improve the quality of the shot they took, such as adjusting the lighting or angle of view. This minimizes the frequency of incomplete or poorly designed submissions, lowering the number of errors produced when processing the data.
Market players in the industry of AI in clinical trials
Medidata Solutions (Dassault Systems)
Conclusion
Although ML has great promise for improving the effectiveness and reliability of clinical research, many substantial challenges remain (some of which have already been discussed). Further guidance and standard-setting by the FDA and other regulatory agencies on transparency, oversight, and data quality in AI-ML processes will be required to reduce risks and discriminatory outcomes in clinical trials, in addition to the unresolved issues of inherent bias, informed consent, and so on, which companies must address with their algorithms. Until then, interest for ML's potential applications in clinical trials is likely to outweigh actual utilization.
AI has the potential to accelerate trial cycles and patient outcomes by aggregating data in ways that increase recruitment, adherence, and data analysis. AI is likely to be the most innovative new technology in drug development since it unlocks previously unavailable, complex insights, paves the road for automation, and accelerates the entire clinical trial value chain. As AI advances and industry standards catch up, more powerful tools will be accessible to accelerate medication development. These tools will assist firms in recruiting a broader spectrum of people, keeping them interested in the study for longer periods of time, speeding up trials, reducing costs, and increasing the amount of data that can be reused. However, AI still has a long way to go before being broadly embraced by the clinical trial community.
